---
title: "mgc1l"
date: "2024-07-14"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[gastric cancer]]

# mgc1l

- ESOPEC demonstrated a superior EFS and OS of FLOT over FOFOX.
- No data now regarding using adjuvant Nivolumab +/- Ipilimumab.
- For mG/EGJ cancer without biomarkers, ARMANI study showed superior PFS and OS by early switch to ramucirumab + paclitaxel.
- RENAISSANCE study demonstrated that radical surgery for limited metastases did not improve OS for mG/EGJ cancer.
- Novel agents emerged quickly to provide GC patients with better survivals.
- EDGE study:promising activity of anti-TIGT plus anti-PD1 in first-line treatment for mG/EGJ cancer.
  Claudin 18.2 ADC showed promising activity in late line.

---
- [[renasisance_gastric.md|RENASISANCE_Gastric]]
- [[armani.md|ARMANI]] phase III
- [[nivofgfr2.md|NIVOFGFR2]]
